Interestingly, the 3 most common alterations target CREBBP, KMT2D, and EZH2 and, in addition to their B-cell intrinsic activity, have all been shown to impact on the capacity of tumor B cells to interact with, and eventually modify, their TME (Figure 3). Here, EZH2 is linked to neoplasm.